Both Cervarix and Gardasil were tested in young adolescents 9/10–15 years of age who were seronegative at study entry for the vaccine-relevant HPV types for safety and antibody responses.

Cervarix from GSK is designed to prevent infection ... Another version of this vaccine, Gardasil 9 or Gardasil Nano, is ...

The next HPV vaccine approved in the United States, called Cervarix, is a bivalent vaccine that protects against HPV types 16 and 18 and was approved for use in females ages 9 to 26. Gardasil 9 ...

Gardasil ® (Merck) and Cervarix ® (GSK) have been positively evaluated in women up to 55 years of age. They are inducing robust responses in HIV-positive individuals. Gardasil has been used for ...

On the plus side, if GSK can show that Cervarix offers a more durable response than Gardasil, it could make substantial inroads into the latter's market share. As the vaccines market continues to ...